Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer

Detalles Bibliográficos
Autores principales: Mendoza-Posada, Daniel, Vela-Chavez, Teresa, Bargallo-Rocha, Enrique, Villafañe, Nestor, Gamboa-Vignole, Carlos, Arce, Claudia
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Meeting Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1796552/
https://www.ncbi.nlm.nih.gov/pubmed/17291331
http://dx.doi.org/10.1186/1471-2407-7-S1-A1
_version_ 1782132226713976832
author Mendoza-Posada, Daniel
Vela-Chavez, Teresa
Bargallo-Rocha, Enrique
Villafañe, Nestor
Gamboa-Vignole, Carlos
Arce, Claudia
author_facet Mendoza-Posada, Daniel
Vela-Chavez, Teresa
Bargallo-Rocha, Enrique
Villafañe, Nestor
Gamboa-Vignole, Carlos
Arce, Claudia
author_sort Mendoza-Posada, Daniel
collection PubMed
description
format Text
id pubmed-1796552
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-17965522007-02-09 Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer Mendoza-Posada, Daniel Vela-Chavez, Teresa Bargallo-Rocha, Enrique Villafañe, Nestor Gamboa-Vignole, Carlos Arce, Claudia BMC Cancer Meeting Abstract BioMed Central 2007-02-05 /pmc/articles/PMC1796552/ /pubmed/17291331 http://dx.doi.org/10.1186/1471-2407-7-S1-A1 Text en Copyright © 2007 Mendoza-Posada et al; licensee BioMed Central Ltd.
spellingShingle Meeting Abstract
Mendoza-Posada, Daniel
Vela-Chavez, Teresa
Bargallo-Rocha, Enrique
Villafañe, Nestor
Gamboa-Vignole, Carlos
Arce, Claudia
Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
title Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
title_full Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
title_fullStr Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
title_full_unstemmed Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
title_short Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
title_sort adriamycin-cyclophosphamide (ac) followed by paclitaxel-cisplatin (pc). a highly active neoadjuvant regimen in locally advanced breast cancer
topic Meeting Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1796552/
https://www.ncbi.nlm.nih.gov/pubmed/17291331
http://dx.doi.org/10.1186/1471-2407-7-S1-A1
work_keys_str_mv AT mendozaposadadaniel adriamycincyclophosphamideacfollowedbypaclitaxelcisplatinpcahighlyactiveneoadjuvantregimeninlocallyadvancedbreastcancer
AT velachavezteresa adriamycincyclophosphamideacfollowedbypaclitaxelcisplatinpcahighlyactiveneoadjuvantregimeninlocallyadvancedbreastcancer
AT bargallorochaenrique adriamycincyclophosphamideacfollowedbypaclitaxelcisplatinpcahighlyactiveneoadjuvantregimeninlocallyadvancedbreastcancer
AT villafanenestor adriamycincyclophosphamideacfollowedbypaclitaxelcisplatinpcahighlyactiveneoadjuvantregimeninlocallyadvancedbreastcancer
AT gamboavignolecarlos adriamycincyclophosphamideacfollowedbypaclitaxelcisplatinpcahighlyactiveneoadjuvantregimeninlocallyadvancedbreastcancer
AT arceclaudia adriamycincyclophosphamideacfollowedbypaclitaxelcisplatinpcahighlyactiveneoadjuvantregimeninlocallyadvancedbreastcancer

Ejemplares similares